Ocugen, Inc.

Ocugen, Inc. is a clinical-stage biopharmaceutical company focused on developing gene therapies to cure blindness diseases. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania. Ocugen, Inc. is dedicated to researching, developing and commercializing treatments for blinding diseases of the retina. These diseases include retinitis pigmentosa, leber congenital amaurosis, dry age-related macular degeneration (AMD), diabetic macular edema, and diabetic retinopathy.

The company’s lead product candidate, OCU400, is a novel gene therapy designed to restore retinal integrity and function for a range of inherited retinal diseases. OCU400 is currently in preclinical development, and Ocugen, Inc. is actively increasing its clinical development portfolio. Additionally, OCU200 is a novel fusion protein in preclinical development for the treatment of the same three diseases: diabetic macular edema, diabetic retinopathy, and wet AMD.

In addition to its internal development, Ocugen, Inc. has established strategic partnerships with CanSino Biologics Inc. and Bharat Biotech. The partnership with CanSino Biologics Inc. is aimed at developing and manufacturing gene therapy products, while the partnership with Bharat Biotech is intended to help with commercializing COVAXIN in the United States market.

Ocugen, Inc. is committed to its mission of advancing innovative treatments for blinding diseases. Through their internal research and development, as well as their strategic partnerships, the company has the capacity to discover and bring to market new treatments that can restore vision and improve the quality of life for people suffering from blinding diseases. The company has strong ties to the local community in Malvern, Pennsylvania, through its Chief Scientific Officer, Dr. Shankar Musunuri, and its Group Co-Chairman, Dr. Peter D. Friedli. Recently, Ocugen, Inc. announced a collaboration with the California Institute for Regenerative Medicine (CIRM) to develop and commercialize ocular gene therapies for blinding diseases. This collaboration will provide a valuable resource for the company to further develop their gene therapies and bring them to market.